A nucleus-targeting peptide antagonist towards EZH2 displays therapeutic efficacy for lung cancer.

[1]  Jintuan Huang,et al.  NGFR Increases the Chemosensitivity of Colorectal Cancer Cells by Enhancing the Apoptotic and Autophagic Effects of 5-fluorouracil via the Activation of S100A9 , 2021, Frontiers in Oncology.

[2]  Jian Liu,et al.  Enhanced lymphatic delivery of nanomicelles encapsulating CXCR4-recognizing peptide and doxorubicin for the treatment of breast cancer. , 2020, International journal of pharmaceutics.

[3]  Robin L. Jones,et al.  Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. , 2020, The Lancet. Oncology.

[4]  J. Meng,et al.  Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia. , 2020, Small.

[5]  Sheridan M. Hoy Tazemetostat: First Approval , 2020, Drugs.

[6]  O. Elemento,et al.  Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. , 2020, Cell reports.

[7]  N. Reguart,et al.  In Search of the Long-Desired ‘Copernican Therapeutic Revolution’ in Small-Cell Lung Cancer , 2020, Drugs.

[8]  Vrinda Gote,et al.  Long-term delivery of protein and peptide therapeutics for cancer therapies , 2019, Expert opinion on drug delivery.

[9]  A. Russo,et al.  Therapeutic Approaches Targeting Nucleolus in Cancer , 2019, Cells.

[10]  A. Mansfield,et al.  Current Diagnosis and Management of Small-Cell Lung Cancer. , 2019, Mayo Clinic proceedings.

[11]  Euan J. Rodger,et al.  Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. , 2019, Trends in immunology.

[12]  J. Poyet,et al.  Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies , 2019, Molecules.

[13]  Qian Li,et al.  Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential , 2018, Biomarker Research.

[14]  W. Béguelin,et al.  Enhancer of zeste homolog 2 (EZH2) inhibitors , 2018, Leukemia & lymphoma.

[15]  L. Tutar,et al.  Tumor Targeting of Polymeric Nanoparticles Conjugated with Peptides, Saccharides, and Small Molecules for Anticancer Drugs. , 2018, Current pharmaceutical design.

[16]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[17]  K. Uchimaru,et al.  Targeting EZH2 in cancer therapy , 2017, Current opinion in oncology.

[18]  Haiyan Xu,et al.  Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5 , 2017, PloS one.

[19]  C. Rudin,et al.  Unravelling the biology of SCLC: implications for therapy , 2017, Nature Reviews Clinical Oncology.

[20]  C. Rudin,et al.  Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. , 2017, Cancer cell.

[21]  J. Meng,et al.  A HSP60-targeting peptide for cell apoptosis imaging , 2016, Oncogenesis.

[22]  C. Roberts,et al.  Targeting EZH2 in cancer , 2016, Nature Medicine.

[23]  B. Tang,et al.  Peptide-Based Treatment: A Promising Cancer Therapy , 2015, Journal of immunology research.

[24]  M. T. McCabe,et al.  EZH2 as a potential target in cancer therapy. , 2014, Epigenomics.

[25]  G. Liang,et al.  Peptide-based nanostructures for cancer diagnosis and therapy. , 2014, Current medicinal chemistry.

[26]  Bradley P. Coe,et al.  EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle Regulation , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  Xiaoyan Xiao,et al.  The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma. , 2012, Oncology reports.

[28]  Jing Wang,et al.  Delivery of drugs to cell membranes by encapsulation in PEG-PE micelles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[29]  E. Greer,et al.  Histone methylation: a dynamic mark in health, disease and inheritance , 2012, Nature Reviews Genetics.

[30]  Andrew J. Bannister,et al.  Regulation of chromatin by histone modifications , 2011, Cell Research.

[31]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[32]  Robert Brown,et al.  Ovarian Cancer Stem Cell–Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2 , 2011, Molecular Cancer Therapeutics.

[33]  Jing Wang,et al.  Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo , 2010, Cancer biology & therapy.

[34]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[35]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[36]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[37]  Steven F Dowdy,et al.  Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. , 2005, Advanced drug delivery reviews.

[38]  E. Snyder,et al.  Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide , 2004, PLoS biology.

[39]  Vladimir P Torchilin,et al.  Peptide and protein drug delivery to and into tumors: challenges and solutions. , 2003, Drug discovery today.

[40]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[41]  S. Dowdy,et al.  Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. , 1999, Cancer research.

[42]  G. Crabtree,et al.  Affinity modulation of small-molecule ligands by borrowing endogenous protein surfaces. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Natalie A. Lissy,et al.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration , 1998, Nature Medicine.

[44]  Priscille Brodin,et al.  A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus* , 1997, The Journal of Biological Chemistry.

[45]  M. Broggini,et al.  p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. , 1997, Cancer research.

[46]  Carl O. Pabo,et al.  Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.

[47]  Maurice Green,et al.  Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein , 1988, Cell.

[48]  M. Magzoub,et al.  Cancer targeting peptides , 2019, Cellular and Molecular Life Sciences.

[49]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[50]  T. Hoffmann,et al.  Peptide therapeutics: current status and future directions. , 2015, Drug discovery today.